JW Pharmaceutical·VORONOI, Joint develpoment of targeting STAT3 in anticancer field - mk.co.kr On December 2, JW Pharmaceutical inked a deal with Korean biotech startup Voronoi to develop next-generation innovative new drugs. It plans to develop a next-generation innovative new drug with global competitiveness by combining JW Pharmaceutical's small molecule anticancer drug candidate of targeting STAT3 with Voronoi's protein decomposition technology 'Protein Degrader(PROTAC; Proteolysis-targeting chimera)'. 기사 전문보기
About voronoiioThis author has not yet filled in any details.
So far voronoiio has created 10 blog entries.
voronoiio2021-11-09T10:00:40+00:00JW Pharmaceutical·VORONOI, Joint develpoment of targeting STAT3 in anticancer fieldvoronoiio2021-11-09T10:00:40+00:00
Nathanael Gray and Eric Fischer along with Deerfield Management create new Center for Protein Degradation at DFCIvoronoiio2019-07-04T18:21:55+00:00
Dana-Farber Cancer Institute and Deerfield Management announced today an up to $80 million collaboration to create the Center for Protein Degradation at Dana-Farber to be led by BCMP Faculty members, Nathanael Gray and Eric Fischer,.